Oncolytics Biotech aims to price public sale of stock with greenshoe

Deal funds company's clinical trial program and manufacturing program

By Devika Patel

Knoxville, Tenn., Feb. 19 - Oncolytics Biotech Inc. said it plans to price a public offering of common stock in the context of the market. The deal will have a 30-day, 15% greenshoe.

Piper Jaffray & Co. and Wedbush PacGrow Life Sciences are the joint bookrunning managers; Paradigm Capital Inc. is the co-manager.

Proceeds will be used for the company's clinical trial program, manufacturing program and general corporate and working capital purposes.

Oncolytics Biotech is a biotechnology company based in Calgary, Alta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.